Eckert & Ziegler and AtomVie Sign Global Agreement for Lu-177 Supply

• Eckert & Ziegler SE and AtomVie Global Radiopharma Inc. have signed a global supply agreement for Lutetium-177 chloride (Theralugand®).

• The partnership supports AtomVie’s CDMO activities in radiopharmaceutical manufacturing, covering early- and late-stage development.

Eckert & Ziegler SE and AtomVie Global Radiopharma Inc. have entered into a global supply agreement for Lutetium-177 chloride (n.c.a. Lu-177, Theralugand®). The deal ensures AtomVie has a steady supply of Theralugand® to support its contract manufacturing activities in radiopharmaceuticals.

The agreement spans both early and late-stage development programs, extending to global pharmaceutical partners. By securing a consistent Lu-177 supply, AtomVie can further develop radiopharmaceutical therapies at its facility. The partnership also provides flexibility to address regulatory needs across different markets.

“We are happy to support AtomVie in advancing global radiopharmaceutical development programs with Theralugand®,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. “By providing our high-quality radionuclides, we vitally contribute to the further development of therapeutic approaches in nuclear medicine.”

Bruno Paquin, CEO of AtomVie, emphasized the significance of the agreement, highlighting that the upcoming launch of AtomVie’s new facility will enhance its manufacturing capabilities. “Partnering with Eckert & Ziegler is a significant step in ensuring that our global partners developing Lutetium-177 based radiopharmaceuticals have the support they need,” he stated.